Trump says he slashed red tape for vaccines, therapies
Get Alerts GILD Hot Sheet
Join SI Premium – FREE
(Updated - March 19, 2020 11:48 AM EDT)
(Updated - March 19, 2020 11:46 AM EDT)
(Updated - March 19, 2020 11:45 AM EDT)
(Updated - March 19, 2020 11:39 AM EDT)
- Trump Begins Press Conference, Still Using "China Virus"
- Working with both parties to further coronavirus legislation
- Trump says if people had known about it, virus could have been stopped, stopped in China
- Trump says he slashed red tape for vaccines, therapies
- "Clinical trials are already underway for many new therapies. We’re working on scaling these to allow many more Americans to access many more drugs that have shown really good promise"
- "If treatments known to be safe in Europe, Japan, other nations, we’ll use that information to protect the health and safety of the American people"
- Chloroquine - malaria drug, around for a long time, very powerful - but nice part is it’s been around for a long time.
- Chloroquine has shown very encouraging early results. We’re going to be able to make that drug available almost immediately. FDA has gone through approval process, it’s been approved - took it down from many, many months to immediate
- Gilead Sciences (NASDAQ: GILD) drug mentioned by Trump as being very closed to being approved for coronavirus
- "There are promising therapies produced by Gilead, remdesivir. That drug also has been approved or very close to approved in that case by the FDA."
- Regeneron (NASDAQ: REGN) drug mentioned in by Trump
- remdesivir, chloroquine and hyroxychloroquine. Those are out now, essentially approved for prescribed use
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- BofA maintains underperform ratings on six BDC stocks
- RenovoRx regains Nasdaq minimum bid price compliance
Create E-mail Alert Related Categories
General News, Politics, Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share